Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29276882 | 0.81 | — | — | |
| SCHEMBL2661186 | 0.80 | ALDH1A1 (0.41) | RORCMEN1KMT2AL3MBTL1KDM1A | |
| SCHEMBL24181745 | 0.75 | — | — | |
| SCHEMBL28175233 | 0.73 | NPC1 (0.50) | RORCL3MBTL1KDM1A | |
| SCHEMBL2660805 | 0.73 | ALDH1A1 (0.45) | MEN1GAAKMT2A | |
| SCHEMBL25181261 | 0.71 | — | — | |
| SCHEMBL23632983 | 0.70 | IRAK4 (0.41) | MEN1GAAMAPTKMT2AL3MBTL1 | |
| SCHEMBL28884071 | 0.70 | — | — | |
| SCHEMBL31637679 | 0.68 | CSNK2A2 (0.41) | — | |
| SCHEMBL31176818 | 0.68 | HPGD (0.41) | MEN1GAAMAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085578-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-21 | — | — | US | disclosed |
| US-20150045349-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2015-02-12 | — | — | US | disclosed |
| EP-2818473-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045349-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | RORC 232/4885MEN1 1167/4885GAA 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.